About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

Eli Lilly (LLY.N): Acquired Kelonia Therapeutics for $7 billion in cash, including an upfront payment of $3.25 billion.

2026-04-20

Eli Lilly (LLY.N): Acquired Kelonia Therapeutics for $7 billion in cash, including an upfront payment of $3.25 billion.

Other News
2026-04-20

European stocks opened lower across the board, with the German DAX 30, Spanish IBEX 35, and Euro Stoxx 50 indices all falling by more than 1%.

European stocks opened lower across the board, with the German DAX 30, Spanish IBEX 35, and Euro Stoxx 50 indices all falling by more than 1%.
2026-04-20

- Investors are back on defense after President Donald Trump said yesterday that the U.S. struck and seized an Iranian-flagged cargo ship in the Gulf of Oman. -Kevin Warsh, Trump’s pick to be the next chair of the Federal Reserve, will head to Capito

- Investors are back on defense after President Donald Trump said yesterday that the U.S. struck and seized an Iranian-flagged cargo ship in the Gulf of Oman. -Kevin Warsh, Trump’s pick to be the next chair of the Federal Reserve, will head to Capitol Hill tomorrow for his Senate confirmation hearing, where he will likely face questions about his ties to Silicon Valley. - Buzzy AI startup Cursor is in discussions for a $2 billion fundraising round, a source familiar with the matter said yesterday. The company would be valued at more than $50 million, excluding the investment. - Gaming was once Nvidia’s bread and butter, but games no longer feel prioritized as Nvidia focuses on its more profitable data center chips rather than its lower-margin gaming products. Its data center business now accounts for more than 90% of Nvidia’s revenue.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.